Emergent BioSolutions
Emergent BioSolutions Inc., a leading biopharmaceutical company headquartered in the United States, specialises in developing and manufacturing vaccines and therapeutics for public health threats. Founded in 1998, the company has achieved significant milestones, including the acquisition of key assets that bolster its position in the biodefence and infectious disease sectors. With a strong operational presence across North America and Europe, Emergent BioSolutions focuses on core products such as vaccines for anthrax and smallpox, as well as treatments for opioid overdose. What sets the company apart is its commitment to addressing urgent health needs through innovative solutions and strategic partnerships. Recognised for its expertise in biodefence, Emergent BioSolutions continues to play a pivotal role in enhancing global health security.
DitchCarbon Score
How does Emergent BioSolutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Emergent BioSolutions's score of 11 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Emergent BioSolutions's reported carbon emissions
In 2023, Emergent BioSolutions reported total carbon emissions of approximately 35,292,000 kg CO2e, comprising about 16,856,000 kg CO2e from Scope 1 emissions and about 18,436,000 kg CO2e from Scope 2 emissions. This represents a reduction from 2022, where total emissions were about 40,434,000 kg CO2e, indicating a significant decrease in their carbon footprint. The company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. However, they continue to monitor and report their emissions, with a focus on improving their emissions intensity, which was approximately 13,900 kg CO2e per full-time equivalent employee in 2023. Emergent BioSolutions is committed to addressing its carbon emissions and enhancing sustainability practices, although specific reduction strategies have not been outlined. The company operates within the biopharmaceutical industry, which is increasingly prioritising climate action and emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 19,334,000 | 00,000,000 |
| Scope 2 | 21,099,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Emergent BioSolutions is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
